Soligenix Reports Positive Clinical Data for CTCL Treatment HyBryte

Soligenix Inc. (NASDAQ: SNGX) has reported a clinical update focused on cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. According to the National Cancer Institute, CTCL can cause persistent skin lesions, plaques and tumors, often leading to significant patient burden.

In addition to the interim analysis, the company reported positive results from a study evaluating HyBryte against Valchlor, an existing treatment option for cutaneous T-cell lymphoma. This comparative clinical data represents an important development in the field, as advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options.

Soligenix is demonstrating momentum as it provides both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy. These announcements reinforce the company's focus on developing innovative treatments for serious conditions like CTCL. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.

For more information about BioMedWire, which published this announcement, please visit https://www.BioMedWire.com. The full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors, and is powered by IBN.